The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells

The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells

Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Antimicrobial agents and chemotherapy 2023-05, Vol.65 (5)
Hauptverfasser: Tomita, Yuriko, Takeda, Makoto, Matsuyama, Shutoku
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Favipiravir (T-705, commercial name Avigan), a drug developed to treat influenza virus infection, has been used in some countries as an oral treatment for COVID-19; however, its clinical efficacy in this context is controversial.….
ISSN:1098-6596
DOI:10.1128/AAC.00020-21